Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.

Human pathology - 1 Nov 2009

Walter Otto, Prasad Manju, Lu Shaolei, Quinlan Robert M, Edmiston Kathryn L, Khan Ashraf

Abstract excerpt

IMP3, an oncofetal protein, is a member of the insulin-like growth factor-II (IGF-II) mRNA-binding protein family. Its relevance as a novel biomarker in lung, pancreatic, renal, and cervical adenocarcinoma was recently revealed. However, its role in breast carcinogenesis and tumor progression is not yet established. Basal-like carcinoma was initially identified by gene expression profiling. It accounts for 15% to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ductal, Breast
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Neoplasm Proteins

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Share to RNA-Binding Proteins

Source

Identifiers

PMID: 19695680
DOI: 10.1016/j.humpath.2009.05.005

Genes

IMP3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.PMID 19695680Read ↗

Oncofetal Protein IMP3, a New Cancer BiomarkerSemantic proximity Read ↗

IMP3, a proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast.Semantic proximity Read ↗

The oncofetal protein IMP1 regulates the transcriptomic landscape to drive early events in pancreatic cancer progression and growthSemantic proximity Read ↗

p62/IMP2 stimulates cell migration and reduces cell adhesion in breast cancerSemantic proximity Read ↗

BRCA-mutated Invasive Breast Carcinomas: Immunohistochemical Analysis of Insulin-like Growth Factor II mRNA-binding Protein (IMP3), Cytokeratin 8/18, and Cytokeratin 14.Semantic proximity Read ↗

The oncofetal protein IMP3: a novel grading tool and predictor of poor clinical outcome in human gliomas.Semantic proximity Read ↗

Lower MMP2, FLNA, CFL1 expressions favor invasive micropapillary carcinoma prognosis over ductal carcinoma of the breastSemantic proximity Read ↗

Elevated expression of the <i>IGF2</i> mRNA binding protein 2 (IGF2BP2/IMP2) is linked to short survival and metastasis in esophageal adenocarcinomaSemantic proximity Read ↗

Epithelial membrane protein 3 functions as an oncogene and is regulated by microRNA-765 in primary breast carcinomaSemantic proximity Read ↗

IMP3 promotes TNBC stem cell property through miRNA-34a regulation.Semantic proximity Read ↗

[Diagnosis and prognosis study of breast carcinoma with micropapillary component].Semantic proximity Read ↗

Gene expression profiling revealed MCM3 to be a better marker than Ki67 in prognosis of invasive ductal breast carcinoma patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.